Bone-Specific Complex for Targeted Cell Transformation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell transformation technologies face challenges such as unintended random delivery of inducing factors, potential progression to cancer cells, and low efficiency in transdifferentiation, particularly with viral vectors, which require foreign gene introduction and are not suitable for stable expression in target tissues.
Innovation Solution
A bone-specific complex comprising a bone cell transformation recombinant protein, such as Oct4 with a cell-permeable protein like 30Kc19, conjugated with a bone-targeting molecule like phosphonated near-infrared fluorescent substance P800SO3, allowing for targeted delivery and overexpression of endogenous genes without foreign gene introduction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral vectors are used for cell transformation, then gene delivery capability is improved, but safety and stability deteriorate due to unintended random delivery and potential cancer progression
Solution Approach 1:
The patent uses a bone-targeting molecule as an intermediary carrier to deliver the inducing factor specifically to bone tissue. Instead of using viral vectors that randomly deliver genes throughout the body, the bone-targeting molecule directs the inducing factor precisely to the intended target, eliminating random delivery while maintaining effective gene transfer capability.
Solution Approach 2:
The patent extracts the harmful viral vector component from the gene delivery system while retaining the essential function of inducing factor delivery. By using a non-viral, bone-targeting molecule-based system, the invention removes the safety risks associated with viral vectors (immunogenicity, insertional mutagenesis) while preserving the ability to deliver genetic material to bone tissue.
2Reliability
If foreign genes are introduced for cell transformation, then transformation capability is improved, but stability deteriorates due to foreign gene expression issues
Solution Approach 1:
The patent employs endogenous genes that are already present in the target cells rather than introducing foreign genes. The inducing factor activates or upregulates these existing genes, allowing the cells to perform self-transformation using their own genetic material. This approach ensures stable and sustained expression without the complications of foreign gene integration and expression regulation.
3Productivity
If direct transdifferentiation with virus is applied locally, then cell transformation is achieved, but productivity deteriorates due to low efficiency
Solution Approach 1:
The patent changes the key parameter of delivery specificity by using a bone-targeting molecule with high affinity for bone tissue. This molecular-level parameter change enables the inducing factor to concentrate specifically at the target site, dramatically improving cellular conversion efficiency in bone tissue while simplifying the application process, as the targeting function is built into the molecule itself rather than requiring complex localized delivery procedures.
Data Source
AI summary
The present invention relates to a bone-specific complex and can solve the stability problem of a viral carrier and foreign gene expression technology by inducing overexpression of targeted endogenous genes without the introduction of foreign genes. The present invention allows enhanced efficiency by stably labeling a targeted object and accurately confirming whether or not application is carried out to the targeted object, and thus can efficiently be applied to the field of developing a new protein-based drug technology requiring particular cell transformation such as osteoporosis and direct transdifferentiation.